Faculty of Pharmacy
Faculty
Dana–Farber Cancer Institute
Boston, Estados UnidosPublications in collaboration with researchers from Dana–Farber Cancer Institute (4)
2024
-
Correction to: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial (Nature Communications, (2024), 15, 1, (5251), 10.1038/s41467-024-49121-3)
Nature Communications
-
Correction to: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe (Nature Communications, (2024), 15, 1, (3736), 10.1038/s41467-024-47751-1)
Nature Communications
-
dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe
Nature Communications, Vol. 15, Núm. 1
2011
-
Zfp281 functions as a transcriptional repressor for pluripotency of mouse embryonic stem cells
Stem Cells, Vol. 29, Núm. 11, pp. 1705-1716